Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis

BackgroundDyslipidemia in rheumatoid arthritis (RA) patients is frequently observed, and treatment with anti-rheumatic drugs has an impact on lipid profiles. Pathophysiologically, inflammation leads to decreased blood lipids and lipoproteins; RA treatment reduces inflammation and therefore may increase lipids and lipoproteins. Whether the lipid changes with RA treatment confer an increased risk of cardiovascular disease or just reflect their potentially atheroprotective anti-inflammatory effect is currently unclear due to limited and conflicting data.ObjectiveThe aim of this review is to summarize the current knowledge on the effects of synthetic and biological disease modifying antirheumatic drugs for the treatment of RA on lipid and lipoprotein parameters.ResultsRecent studies on methotrexate emphasize its anti-atherogenic effect. Golimumab combined with methotrexate revealed a trend towards an anti-atherogenic potential. The known pro-atherogenic lipid-spectrum alterations caused by tofacitinib can be effectively treated with atorvastatin. Tocilizumab signals a favorable impact on the extent of lipid modifications when combined with methotrexate. Abatacept indicated a trend towards an anti-atherogenic lipid profile demonstrated by favorable effects on HDL-C and on the TC/HDL-C ratio. Rituximab has beneficial effects on HDL-C and ApoA1, as well as on the ApoB/ApoA1 ratio.Clinical implicationsAnti-rheumatic drugs have various effects on lipid parameters, which in part appear pro-atherogenic. However, because many of these lipid changes may well reflect their potentially atheroprotective anti-inflammatory action the cardiovascular impact of these changes remains unclear. Whatsoever, cardiovascular safety trials for antirheumatic drugs would be valuable.     

酶联免疫吸附试验、间接荧光抗体试验、间接免疫过氧化物酶染色试验诊断人体旋毛虫病的初步研究

用ELISA、IFA和IIP试验检测11例旋毛虫病人血清特异性抗体,阳性率分别为72.72％、81.82％和81.82%。它们之间无统计学差异,3项试验结果间存在良好一致性。 同时检测了30份健康献血员血清和20例其他寄生虫病人血清(包括华支睾吸虫病、四川肺吸虫病、日本血吸虫病、包虫病和阿米巴肝脓肿),旋毛虫病人组的ELISA、IFA和IIP阳性率明显为高。 由于3项免疫学试验均具有较好的特异性和灵敏性,故可以单独或联合用于人体旋毛虫病的诊断和流行病学调查。     

解磷注射液救治急性有机磷农药中毒34例临床报告

将急性有机磷农药中毒患者69例随机分为2组,一组主要应用解磷注射液治疗(新疗法34例),另一组(35例)主要应用阿托品治疗。两组治愈率分别为97.1％及77.1％,疗效比较差异显著(P<0.05)。新疗法的优点是起效快,作用持久,疗程短(两组比较P<0.001),副反应轻,值得推广应用。并就应用方法及注意事项等作了探讨,也强调了早期足量用药的重要性。     

纤维支气管镜与间接喉钳手术治疗声带疾病

目的进一步研究声带小结与息肉的治疗手段。方法采用日本OlimpusBFp20型纤支镜和国产FF-99光电子内窥镜显示仪，配合间接万向喉钳治疗声带小结和息肉57例。结果治愈率92％，病人痛苦小。结论纤支镜配合间接喉钳手术治疗声带小结和息肉效果良好。     

开博通治疗急性心肌梗塞临床观察

目的观察早期服用开博通治疗急性心肌梗塞的近期效果。资料与方法２０１例急性心肌梗塞症状后２４小时内入院且无明显低血压患者，自入院开始后在接受常规治疗基础上，１２８例加服开博通（治疗组），６０例加服安慰剂（对照组），均治疗４周。结果治疗组中前壁梗塞患者的室性心律失常、心力衰竭、梗塞延展发生率、４周病死率以及１年院外猝死率均低于对照组前壁梗塞患者，而下壁梗塞患者无此差异；治疗组中下壁梗塞患者并发房室传导阻滞者高于对照组下壁梗塞患者，而前壁梗塞患者无此差异。结论开博通能降低前壁梗塞患者的住院期重要并发症及早期病死率，且能降低１年院外猝死率。     

食管癌患者与对照组血清维生素A水平分析

目的:为了解食管癌患者和非食管癌患者体内维生素A的水平及其与食管癌发病的关系.方法:采用微量荧光法对32例食管癌患者(实验组)和32例非食管癌患者(对照组)血清中维生素A含量进行了测定.结果:显示实验组与对照组血清维生素A均值分别为1.55μmol/L,1.69μmol/L.经统计学处理两组血清维生素A水平有显著性差异(P<0.01).结论:提示食管癌的发生可能与机体维生素A水平有关,这种关系需进一步探讨.     

“E（疫）”时代背景下大学生心理危机干预体系构建的思考

本文探讨信息时代背景下,在校大学生高发心理危机的原因,并倡导高校教学管理人员充分利用当下信息技术成果对在校大学生进行心理评估和常态化心理教育,并依托当前高校信息化建设平台收集相关信息,构建易感大学生的心理危机预警及干预机制,以期将端口前移,更好地保障在校大学生的心理健康。